4//SEC Filing
Smith Hunter C 4
Accession 0001104659-25-015325
CIK 0001649904other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 9:50 PM ET
Size
13.9 KB
Accession
0001104659-25-015325
Insider Transaction Report
Form 4
Smith Hunter C
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-16+6,600→ 112,144 total - Sale
Common Stock
2025-02-19$57.22/sh−2,215$126,742→ 109,929 total - Award
Restricted Stock Units
2025-02-14+41,650→ 41,650 total→ Common Stock (41,650 underlying) - Award
Stock Options (Right to Buy)
2025-02-14+62,500→ 62,500 totalExercise: $56.69Exp: 2035-02-13→ Common Stock (62,500 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-16−6,600→ 19,800 total→ Common Stock (6,600 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F3]The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
- [F4]The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F5]The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.
Documents
Issuer
RHYTHM PHARMACEUTICALS, INC.
CIK 0001649904
Entity typeother
Related Parties
1- filerCIK 0001636385
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 9:50 PM ET
- Size
- 13.9 KB